When compared with L-type CCB, N-/T-type CCB significantly reduced urine albumin/protein excretion in CKD patients who were treated with RAS inhibitors (SMD, −0.41; 95% CI, −0.64 to −0.18; p < 0.001) (Table 2, Figure 3). Here, ALB is linked to chronic kidney disease.